

COMMON QUESTIONS YOU MAY HAVE

1. If my IBRANCE treatment has been interrupted at any time, but I have proof of purchase of 11 packs of IBRANCE from a New Zealand Pharmacy, will I still be eligible?

Yes, as long as you have proof of purchase of 11 IBRANCE packs from a New Zealand pharmacy, you will remain eligible.

2. Will I need to pay for anything when I receive my IBRANCE at No Charge*?

Yes, a pharmacy dispensing fee will still apply to your No Charge* IBRANCE.

3. Can I receive more than 2 packs of IBRANCE at one time?

No, you will receive only 2 No Charge* packs of IBRANCE at one time as your oncologist needs to confirm that you are receiving a clinical benefit.

4. After I have paid for 11 IBRANCE and received my first 2 packs of IBRANCE at No Charge*, how do I access my next IBRANCE packs at No Charge*?

Midway through your last IBRANCE pack at No Charge* (day 15), please contact your pharmacy to allow enough time to confirm with your oncologist that you are still receiving a clinical benefit from IBRANCE and time for processing your next order. Allow at least 10 working days for processing

5. I have purchased IBRANCE from overseas, are these valid towards this program?

Only purchases from a New Zealand pharmacy are valid

No Charge* IBRANCE is defined as IBRANCE for patients who have been prescribed IBRANCE in New Zealand for HR+, HER2- advanced breast cancer and are taking IBRANCE in combination with an aromatase inhibitor or fulvestrant, AND who are able to provide proof of purchase of 11 packs of IBRANCE from a New Zealand pharmacy, completed the application form and have a valid prescription for ongoing packs. AND their oncologist deems them to not to have progressed and still clinically benefiting from treatment. Packs will be distributed two at a time, and each distribution requires written confirmation from the oncologist that the patient is still clinically benefiting and remains progression free. IBRANCE will be supplied at the dose prescribed on the prescription and sent to the patient's pharmacy as per the application form. A pharmacy dispensing fee will apply on any No Charge* IBRANCE stock. **Pfizer has the right to stop/alter this program at any time. Notice will be provided in advance of any changes to this program. At any point in time palbociclib is funded, the IBRANCE Assistance Program will close.** A New Zealand patient is defined as a citizen or resident of New Zealand.

IBRANCE® (palbociclib 75 mg, 100 mg and 125 mg) Capsules

IBRANCE (palbociclib) is an unfunded prescription medicine used to treat HR+, HER2- advanced breast cancer taken in combination with an aromatase inhibitor or fulvestrant. IBRANCE has risks and benefits. Do not take IBRANCE if you are allergic to palbociclib or any of the other ingredients in IBRANCE capsules. Caution is needed if you are premenopausal or perimenopausal, have or have had abnormal blood test results, problems with your liver or kidneys, are lactose intolerant, are pregnant or planning to become pregnant or are breastfeeding. Tell your doctor if you are taking any other medicines. Common side effects include infection, abnormal blood test results, tiredness, feeling sick or vomiting, diarrhoea, sore mouth, lips or tongue, hair loss, loss of appetite, nose bleed, skin rash, change in sense of taste, blurred vision, increased tearing or dry eyes, shortness of breath, bleeding or bruising more easily than usual. If symptoms continue or you have side effects, see your doctor, pharmacist or healthcare professional. Ask your doctor if IBRANCE is right for you. Use strictly as directed. Contains 75 mg, 100 mg or 125 mg of palbociclib. You will need to pay for this medicine and normal doctor's fees apply. Further information on IBRANCE is available from Medsafe www.medsafe.govt.nz or Pfizer New Zealand Limited, Auckland, www.pfizer.co.nz Ph. 0800 736 363. V10817 Pfizer New Zealand Auckland. PZR0439 PP-IBR-NZL-0039 TAPS NA 9773 Date of preparation September 2018. Ibrance® is a registered trademark. © Pfizer 2018



IBRANCE® ASSISTANCE PROGRAM INFORMATION FOR PATIENTS

ABOUT IBRANCE

IBRANCE (palbociclib) is a prescription medicine used to treat a certain type of breast cancer (hormone receptor (HR+) positive, human epidermal growth factor receptor 2 (HER2-) negative advanced or metastatic breast cancer). It is given together with an aromatase inhibitor or fulvestrant, which are used as hormonal anticancer therapies.

As IBRANCE is currently not funded by PHARMAC, to access IBRANCE you will need to pay for treatment.

IBRANCE®
palbociclib

WHAT IS THE IBRANCE ASSISTANCE PROGRAM?

To help make IBRANCE more accessible, Pfizer has introduced an Assistance Program to reduce some of the cost of your IBRANCE treatment. Speak to your treating oncologist to determine if you meet the eligibility criteria for the IBRANCE Assistance Program.

HOW DOES THE IBRANCE ASSISTANCE PROGRAM WORK?

After purchasing **11 IBRANCE packs** from a New Zealand pharmacy, your **IBRANCE packs will be at No Charge* thereafter** when the eligibility criteria are met. Each pack contains capsules for 28 days of treatment.

This means if eligible you will pay for **11 IBRANCE packs only.**
(a pharmacy dispensing fee will still apply to No Charge* IBRANCE packs).

Illustration of how the program works:



Pfizer will send **2 packs of IBRANCE at No Charge*** at a time to your designated pharmacy on the application form once your eligibility is determined. The next **2 IBRANCE packs at No Charge*** will be sent at the end of the second month upon oncologist eligibility reconfirmation.

IBRANCE will only be supplied at No Charge* if your treating oncologist deems ongoing treatment is of clinical benefit and you have not progressed.

* Eligibility criteria detailed overleaf

WHO IS ELIGIBLE FOR THE IBRANCE ASSISTANCE PROGRAM?

To be eligible for the IBRANCE Assistance Program, you must be a New Zealand patient who has fulfilled each of the following criteria:

1. Been prescribed IBRANCE for HR+, HER2- advanced or metastatic breast cancer and are taking IBRANCE in combination with:
 - an aromatase inhibitor
 - OR fulvestrant after prior endocrine therapy
2. Purchased **11 packs** of IBRANCE from a New Zealand pharmacy and can provide proof of purchase
3. **A valid prescription** for packs of IBRANCE has been sent to the pharmacy
4. **Written oncologist confirmation** that you continue to receive clinical benefit and have not progressed on treatment after purchasing 11 packs of IBRANCE. This will be required after every **2 packs of IBRANCE**
5. A completed and **submitted application form at least 10 working days prior to requiring IBRANCE in pharmacy**

Patients will only be eligible for subsequent No Charge* IBRANCE if they continue to meet the criteria.

If the IBRANCE treatment has been interrupted at any time, as long as the patient has proof of purchase of 11 IBRANCE packs from a New Zealand pharmacy, patients remain eligible.